Healthcare Industry News: S.A.
News Release - February 1, 2022
BD Expands from Cancer Discovery and Diagnosis into Post-Treatment Monitoring with Acquisition of Cytognos from Vitro S.A.
Informatics Capabilities Help Expand BD Data Analytics CapabilitieS.A.d UnderS.A.ding of Cancer and Other Chronic DiS.A.esFRANKLIN LAKES, N.J., Feb. 1, 2022 -- (Healthcare Sales & Marketing Network) -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has completed the acquisition of Cytognos, a privately held company headquartered in Salamanca, S.A.n, specializing in flow cytometry solutions for blood cancer diagnosis, minimal residual diS.A.e (MRD) detection and immune monitoring reS.A.ch for blood diS.A.es.
The acquisition of CytognoS.A.celerates BD's strategy to support chronic diS.A.e management by expanding its portfolio of blood cancer diagnostics, immune assessment testS.A.d informatics to address patient, clinician and care provider needs to better underS.A.d the immune system, immune response and MRD. By monitoring for MRD, lab managerS.A.d physicians can detect low levels of cancer cells following treatment that alerts them if the diS.A.e is still present or if there iS.A.signal of recurrence. This iS.A.key element of the patient care continuum that helps clinicianS.A.d physicians recognize when cancer recurS.A.d aids in the timely treatment of patients.
"As the underS.A.ding and treatment of cancer evolveS.A.d improves, the importance of monitoring post remission cancer survivors has become paramount to improve patient outcomes," said Puneet Sarin, worldwide president of BD Biosciences. "Cytognos' capabilitieS.A.e complementary to those already developed by BD scientists to screen for the most common blood cancerS.A.d will enable BD to expand beyond cancer discovery and diagnosis into the monitoring phase of the patient's journey. We're building on our strong track record of identifying and executing on opportunitieS.A.d then integrating those new productS.A.d businesses into our portfolio."
With the acquisition of Cytognos, BD gains exclusive access to advanced aS.A.s licensed from the EuroFlow™ Consortium, a scientifically independent network in the fields of hematology and immunology with scientistS.A.d reS.A.chers from more than 20 European universitieS.A.d hospitals. BD has existing license agreements with EuroFlow for multiple other aS.A.S.A.d the addition of the CytognoS.A.says further strengthens BD's 12-year licensing collaboration with EuroFlow.
"Cytognos has 25 years of experience successfully designing, developing, manufacturing and commercializing innovative flow cytometry products for in vitro diagnosticS.A.d life science reS.A.ch use," said Fernando Martin de Lara, Cytognos CEO, who will continue as the business leader for this specific element of BDB's portfolio. "We are pleased to be joining a global health care leader with robust infrastructure and deep expertise to accelerate growth of a combined BD/Cytognos offering by expanding the reach of Cytognos' solutions."
Cytognos' key products increase BD's comprehensive portfolio of diagnostic and reS.A.ch solutions for certain types of cancers that use flow cytometry as the primary means of discovery, diagnosiS.A.d underS.A.ding, including lymphoma, leukemia and multiple myeloma. Cytognos IVD productS.A.e CE marked and available only in Europe and other countries where regulatory approval of the products has been obtained. They are not available for sale in the U.S. In addition, Cytognos provides several reS.A.ch aS.A.s for multiple myeloma MRD and immune monitoring, which expands BD's portfolio in this S.A.e. Cytognos' approximately 80 employees will join BD aS.A.result of the acquisition.
CytognoS.A.so brings sophisticated informatics solutions that will further BD's leadership in the growing area of immunology and enable the company to expand its flow informatics offerings. In a world of limited resourceS.A.d increasing data and settings, Cytognos technology offerS.A.powerful, intuitive way that provideS.A.better underS.A.ding of patient data.
Cytognos, which is celebrating the 25-year anniversary since its foundation, waS.A.division of Vitro, a S.A.ish diagnostics company that develops, produceS.A.d sells fully integrated reagents, hardware and software platforms.
Terms of the transaction were not disclosed. The transaction is expected to be immaterial to BD's fiS.A. 2022 financial results. Cytognos financial results will be reported under the Biosciences business within the Life Sciences segment.
About BD
BD is one of the largest global medical technology companies in the world and iS.A.vancing the world of health by improving medical discovery, diagnosticS.A.d the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, serviceS.A.d solutions that help advance both clinical therapy for patientS.A.d clinical process for health care providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect diS.A.e and advance reS.A.chers' capabilities to develop the next generation of diagnosticS.A.d therapeutics. BD haS.A.presence in virtually every country and partners with organizationS.A.ound the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.
Source: Becton, Dickinson
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!